Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
for Non Small Cell Lung Carcinoma
26 locations incl. Phoenix
Sponsor: AbbVie
Sex: All·Age: 18+
Code: NCT06772623·Phase 1, Phase 2·Recruiting